These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 16516013)
1. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Crawford ED; Wilson SS; McConnell JD; Slawin KM; Lieber MC; Smith JA; Meehan AG; Bautista OM; Noble WR; Kusek JW; Nyberg LM; Roehrborn CG; J Urol; 2006 Apr; 175(4):1422-6; discussion 1426-7. PubMed ID: 16516013 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM; J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915 [TBL] [Abstract][Full Text] [Related]
3. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA; N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504 [TBL] [Abstract][Full Text] [Related]
4. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. Roehrborn CG BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764 [TBL] [Abstract][Full Text] [Related]
5. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. Roehrborn CG BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681 [TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. McDonald H; Hux M; Brisson M; Bernard L; Nickel JC Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054 [TBL] [Abstract][Full Text] [Related]
7. The natural history of benign prostatic hyperplasia. Fitzpatrick JM BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045 [TBL] [Abstract][Full Text] [Related]
8. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J; J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299 [TBL] [Abstract][Full Text] [Related]
9. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
10. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability]. Gratzke P; Kirby RS Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491 [TBL] [Abstract][Full Text] [Related]
11. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667 [TBL] [Abstract][Full Text] [Related]
12. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Naslund MJ; Miner M Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044 [TBL] [Abstract][Full Text] [Related]
13. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. Trachtenberg J BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB; Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. Fwu CW; Eggers PW; Kaplan SA; Kirkali Z; Lee JY; Kusek JW J Urol; 2013 Jul; 190(1):187-93. PubMed ID: 23357210 [TBL] [Abstract][Full Text] [Related]
16. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F; Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011 [TBL] [Abstract][Full Text] [Related]
18. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia]. de la Taille A Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085 [TBL] [Abstract][Full Text] [Related]
19. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. Johnson TM; Burrows PK; Kusek JW; Nyberg LM; Tenover JL; Lepor H; Roehrborn CG; J Urol; 2007 Nov; 178(5):2045-50; discussion 2050-1. PubMed ID: 17869295 [TBL] [Abstract][Full Text] [Related]